Theory Paper IDrNB Cardiology – Theory Notes

POLYGENIC RISK SCORES (PRS) IN CARDIOVASCULAR DISEASE PREDICTION

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE CONCEPTUAL RATIONALE: MONOGENIC VS. POLYGENIC ARCHITECTURE

  • The Monogenic Limitation: Rare, high-penetrance monogenic mutations—such as pathogenic variants in LDLR, APOB, or PCSK9 causing Familial Hypercholesterolemia (FH) (prevalence ~1 in 250 to 310)—confer a 3- to 4-fold increased risk of premature Coronary Artery Disease (CAD), but are identified in less than 2 to 5 percent of patients presenting with early-onset myocardial infarction.
  • The Polygenic Reality (Khera et al., Nature Genetics 2018): In the vast majority of individuals, inherited susceptibility to CAD (as well as Atrial Fibrillation, Hypertension, and Type 2 Diabetes) is driven by the additive cumulative burden of thousands to millions of common Single Nucleotide Polymorphisms (SNPs) distributed across the genome. While any single common SNP exerts a tiny effect size (odds ratio 1.02 to 1.15), their aggregated genome-wide sum produces a wide Gaussian distribution of lifetime genetic risk.
  • Mathematical Construction of a Genome-Wide Polygenic Risk Score (GPS / PRS): Calculated as the weighted sum of risk-associated alleles carried by an individual across M genetic variants (PRS = Sum of [Beta_i x Dosage_i]), where Beta_i is the log-odds effect weight derived from large discovery Genome-Wide Association Studies (GWAS) (e.g., CARDIoGRAMplusC4D, Million Veteran Program, UK Biobank) using linkage-disequilibrium clumping or Bayesian shrinkage algorithms (LDpred, PRS-CS).

IICLINICAL APPLICATION: THE “LIFETIME RISK-ENHANCING” PARADIGM

  • Capture at Birth (Primordial and Early Primary Prevention): Because germline DNA does not change over a lifetime, a Polygenic Risk Score can be calculated from birth or young adulthood (age 20 to 40 years)—decades before age-dependent clinical calculators (such as the 10-year Pooled Cohort Equations, SCORE2, or PREVENT) cross treatment thresholds.
  • The “Polygenic FH Equivalent” (Khera et al., Nature Genetics 2018): In the UK Biobank (n = 288,978), individuals in the top 8 percent (and especially the top 5 percent) of the genome-wide CAD Polygenic Risk Score distribution carry a 3-fold or greater increased risk of CAD—a risk magnitude identical to carrying a monogenic Familial Hypercholesterolemia mutation, yet 15 to 20 times more prevalent in the general population (80 per 1,000 vs. 4 per 1,000 for monogenic FH). Crucially, unlike monogenic FH (which is flagged by LDL-C >190 mg/dL), individuals with a high polygenic CAD score often have normal or borderline lipid and blood pressure levels, rendering them invisible to standard clinical screening.
  • Interaction with Monogenic Mutations: Even among patients who carry a pathogenic monogenic FH (LDLR) or HCM/Brugada/LQTS variant, the background Polygenic Risk Score acts as a potent genetic modifier that explains incomplete penetrance and variable expressivity (e.g., why one family member with an LDLR mutation suffers an MI at age 35 while a sibling with the same mutation remains event-free at age 65).

IIILANDMARK CLINICAL EVIDENCE MATRIX

Clinical Utility Domain Landmark Study / Trial Substudy Key Quantitative Finding & Clinical Implication
Polygenic “FH Equivalent” Identification Khera et al. (Nature Genetics 2018; UK Biobank) Top 8% of CAD PRS confers >=3-fold CAD risk (same as monogenic FH, but 20x more common and not identifiable by LDL-C alone)
Lifestyle Offsets Genetic Risk Khera et al. (NEJM 2016 — “Genetics vs. Lifestyle”) Among patients in the highest genetic risk quintile, adherence to a favorable lifestyle (no smoking, BMI <30, physical activity, healthy diet) reduced 10-year incident CAD events by 46% (“Genetics load the gun, lifestyle pulls the trigger”)
Superior Benefit from Statins & PCSK9 Inhibitors WOSCOPS / JUPITER / ASCOT (Statins) & FOURIER / ODYSSEY OUTCOMES (Circulation 2020 — Evolocumab / Alirocumab) Patients in the highest PRS tier derive a markedly greater relative and absolute risk reduction from Statins (nearly double the relative risk reduction of lower-risk tiers) and PCSK9 inhibitors (37% RRR in high PRS without clinical risk factors; NNT halved)
Integration with Coronary Artery Calcium (CAC) MESA & Rotterdam Study Cohorts (JAMA 2023) CAC remains superior to PRS in older adults (>55 yr), whereas PRS adds strongest reclassification in younger adults (<45–50 yr) before macroscopic calcification develops

IVCURRENT GUIDELINE STATUS (ESC 2021 PREVENTION / ESC 2023 CARDIOMYOPATHY / AHA SCIENTIFIC STATEMENT 2022)

  • General Population Screening (Class III — Not Recommended): The 2021 ESC Guidelines on Cardiovascular Disease Prevention do not recommend routine genetic or polygenic risk scoring in the general population (Class III, Level B) due to modest incremental C-statistic improvement (+0.01 to +0.03) when added to SCORE2 in middle-aged/older cohorts and lack of dedicated randomized clinical trial outcome data.
  • Targeted Clinical Scenarios (AHA 2022 Scientific Statement on PRS / Selective Risk Enhancer):
    • Borderline or Intermediate 10-Year ASCVD Risk (5% to 20%): A high CAD PRS (>=80th to 95th percentile) acts as a risk-enhancing factor that reclassifies 10 to 15 percent of intermediate-risk adults upward to favor early statin initiation.
    • Young Adults (<40 to 45 Years) with Premature Family History: Identifies lifetime genetic vulnerability before CAC becomes positive (>0), guiding early intensive LDL-C/ApoB lowering.
    • Secondary Prevention Intensification: Identifies post-ACS patients in the top PRS decile who derive the greatest absolute MACE reduction from PCSK9 inhibition (FOURIER / ODYSSEY OUTCOMES genetic substudies).

VLIMITATIONS AND THE “EUROCENTRIC DIVERSITY TRAP”

  • Ancestral Transferability Bias: Historically, 75 to 85 percent of GWAS discovery cohorts were of European ancestry. Because allele frequencies, linkage disequilibrium (LD) block structures, and causal effect sizes differ across ancestral groups, European-derived PRSs show significantly degraded predictive accuracy (by 30 to 70 percent in African ancestry and 15 to 30 percent in South Asian ancestry) unless calibrated using multi-ancestry models.
  • Non-Genetic Determinants: A PRS captures only common germline additive variance (heritability of CAD is ~40 to 50 percent); it does not capture somatic clonal hematopoiesis (CHIP — TET2, DNMT3A, ASXL1, JAK2), epigenetic modifications, or acute environmental triggers.

VIPRACTICAL APPLICATION IN THE INDIAN CLINICAL CONTEXT

  • South Asian Multi-Ancestry PRS Development (Wang & Khera et al., JACC 2020; Patel et al., Nature Medicine 2023; GenomeIndia Project): Dedicated South Asian-calibrated Genome-Wide Polygenic Scores (validated in Indian case-control cohorts, PROMIS, and UK Biobank South Asians) demonstrate an odds ratio of 1.6 to 1.7 per standard deviation and identify the top 5 percent of Indians who carry a >3- to 4-fold risk of premature Myocardial Infarction.
  • Highest Clinical Yield in India: In Indian preventive cardiology clinics, combining a South Asian-calibrated PRS with Lipoprotein(a) and Apolipoprotein B in young adults (aged 20 to 45 years) with a family history of premature CAD identifies high-risk individuals during the “CAC-zero window” (when non-calcified lipid-rich soft plaque is forming), justifying early lifestyle intervention and statin therapy.

Key references

  • Khera AV, Chaffin M, Aragam KG, et al.: Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations, Nature Genetics, 2018.
  • Khera AV, Emdin CA, Drake I, et al.: Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease, New England Journal of Medicine, 2016.
  • O’Sullivan JW, Raghavan S, Marquez-Luna C, et al.: Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation, 2022.
  • Marston NA, Kamanu FK, Nordio F, et al. (FOURIER Investigators): Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score, Circulation, 2020.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.